Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of BI 695501 in rheumatoid arthritis after completion of trial 1297.2
2015-002634-41Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab-adbm in rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Primary endpoint: Drug-related adverse events. Started Oct 2015; status: completed.
02
Drugs
adalimumab-adbm
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-002634-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002634-41.